View Clinical Trial (Medical Research Study)


A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease - NCT00890890-33613(Clinical Trial 289490)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup

City:  Tampa
State:  
FL
Zip Code: 33613
Conditions: Alzheimer's Disease
Purpose: The purpose of this study is to determine the safety and tolerability of BMS-708163 in patients with Prodromal Alzheimer's disease over a treatment period of a minimum of 104-weeks. In addition patients will be seen for safety visits at 4 and 12 weeks post treatment.
Study summary:
Criteria: Inclusion Criteria: - Patient meets clinical criteria for prodromal Alzheimer's disease (MMSE 24-30) - Memory complaint by subject or study partner - CSF aβ42 levels < 200pg/mL or Total Tau/aβ42 ratio of ≥ 0.39 - Score of ≤4 on the Modified Hachinski Ischemia Scale - CT results consistent with Alzheimer's disease - Medically stable - 6 years education - Reliable study partner - Must be able to swallow capsules Exclusion Criteria: - Premenopausal women - DSM-IV diagnosis of Dementia History of stroke - Immunocompromised - Active peptic ulcer, GI bleed, chronic inflammatory bowel disease, chronic diarrhea or past GI surgery that would impact drug absorption - Unstable Vitamin B-12 deficiency - Hematologic or solid malignancy within 5 years - Geriatric Depression Scale ≥ 6 - Unstable medical condition - Alcohol or drug abuse history with 12-months of study entry - Significant drug allergy - Prisoners, compulsory psychiatric patients, or residents of nursing home or skilled nursing facility at entry - Any other experimental therapy with 30-days of study entry
Study is available at: University Of South Florida
Tampa, FL 33613
United States

Primary Contact:
Amanda Smith, Site 029
Phone: 813-974-4355

Secondary Contact:
For participation information at a USA site use a phone number below. For site information outside the USA please email:
Email: Clinical.Trials@bms.com
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.

Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:
Only selected fields are shown, please use the link above to view all information about this clinical trial.